Genentech Herceptin
Executive Summary
BLA submitted May 4 for the treatment of women with metastatic breast cancer who have tumors that overexpress the growth factor receptor HER2. Herceptin (trastuzumab) has been designated a "fast track" product and will receive priority review at FDA, the company says